Concord Biotech Limited Cash Flow-to-Debt Ratio
Concord Biotech Limited cash flow-to-debt ratio. Concord Biotech Limited (CONCORDBIO) has a Cash Flow-to-Debt Ratio of 1.12x as of March 2025, meaning its operating cash flow of Rs2.47 Billion could theoretically repay 1% of its total liabilities (Rs2.22 Billion) in one year. Check Concord Biotech Limited cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Concord Biotech Limited (2020–2025)
Cash flow-to-debt ratio of Concord Biotech Limited from 2020 to 2025. Historical debt coverage capacity for Concord Biotech Limited across 6 annual periods. Check Concord Biotech Limited (CONCORDBIO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Concord Biotech Limited Cash Flow-to-Debt Ratio by Year (2020–2025)
Concord Biotech Limited cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Concord Biotech Limited. For the full cash flow conversion analysis, see Concord Biotech Limited cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.12x | Rs2.47 Billion | Rs2.22 Billion | ▼ -26.8% |
| 2024 | 1.53x | Rs2.65 Billion | Rs1.74 Billion | ▲ +38.9% |
| 2023 | 1.10x | Rs2.46 Billion | Rs2.24 Billion | ▲ +10.9% |
| 2022 | 0.99x | Rs2.07 Billion | Rs2.10 Billion | ▲ +8.7% |
| 2021 | 0.91x | Rs1.67 Billion | Rs1.83 Billion | ▲ +0.1% |
| 2020 | 0.91x | Rs1.55 Billion | Rs1.70 Billion | — |